Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
World
Ella Pickover

£1.65m gene-editing therapy offers hope of cure for some blood disorder patients

Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing tool Crispr (Alamy/PA) -

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder hope of a cure.

Campaigners reacted with joy as health officials approved a gene-editing therapy for certain children and adults with severe sickle cell disorder.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.